Chongkundang Health's 'I'm Vita Multivitamin Immune Shot' Surpasses 50 Million Bottles Sold
Chongkundang Health's premium vitamin brand 'I'm Vita' has announced that its flagship product, 'I'm Vita Multivitamin Immune Shot,' has surpassed a cumulative sales volume of 50 million bottles.
'I'm Vita Multivitamin Immune Shot' is a dual-form vitamin that combines liquid and tablet forms, allowing consumers to conveniently replenish their energy with a single bottle per day, which contains a total of 18 essential nutrients.
In particular, the product is formulated with B vitamins at up to 4,000% of the daily recommended intake, making it ideal for consumers seeking an energy boost and increased vitality.
The reliability of the ingredients has also enhanced the product's competitiveness. I'm Vita Immune Shot uses only 100% premium ingredients from DSM, a European company, which has contributed to increased consumer trust and satisfaction with the product.
The market response to the brand has also been positive. I'm Vita was ranked No. 1 in the vitamin category of the 'Korea Brand Power Index (K-BPI)' announced by Korea Management Association Consulting (KMAC) for two consecutive years in 2024 and 2025, demonstrating superiority in both product quality and brand credibility.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Chongkundang Health representative stated, "I'm Vita will continue to strive to support consumers' healthy daily lives."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.